VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ADPT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ADPTAdaptive Biotechnologies Corporation
$28.46$4.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ADPT
  4. Financial Ratios

Adaptive Biotechnologies Corporation (ADPT) Financial Ratios

Latest Ratios: P/E Ratio -75.4x · EV/EBITDA N/A · ROE -27.8%. (2017–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ADPT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$4.6B$2.5B$3.5B$2.8B$4.4B$15.8B$31.0B$14.9B——
Enterprise Value$4.8B$2.7B$3.6B$2.9B$4.4B$15.7B$31.0B$14.8B——
P/E Ratio →-75.41—————————
P/S Ratio15.288.9019.7316.6223.50102.07315.46174.93——
P/B Ratio19.1910.9517.449.189.3826.0841.7626.06——
P/FCF———————76.63——
P/OCF———————72.45——

P/E links to full P/E history page with 30-year chart

ADPT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—9.6519.9616.8223.60101.89315.30174.22——
EV / EBITDA——————————
EV / EBIT——————————
EV / FCF———————76.32——

ADPT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin74.2%74.2%59.7%55.6%68.7%68.1%77.1%73.8%64.7%59.2%
Operating Margin-20.6%-20.6%-90.8%-133.3%-108.0%-135.4%-155.3%-92.1%-89.4%-115.7%
Net Profit Margin-21.5%-21.5%-89.1%-132.3%-108.0%-134.3%-148.6%-80.6%-83.4%-111.4%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE-27.8%-27.8%-62.5%-58.3%-37.5%-30.8%-22.3%-43.8%——
ROA-11.3%-11.3%-26.6%-29.7%-22.5%-20.3%-14.4%-11.0%-13.4%-11.8%
ROIC-12.6%-12.6%-41.6%-41.3%-28.4%-24.0%-18.5%-15.5%-14.9%—
ROCE-13.2%-13.2%-32.0%-34.4%-25.7%-23.0%-16.6%-13.7%-15.3%-13.0%

ADPT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity1.251.250.440.320.230.180.150.06——
Debt / EBITDA——————————
Net Debt / Equity—0.930.200.110.04-0.05-0.02-0.11——
Net Debt / EBITDA——————————
Debt / FCF———————-0.31——
Interest Coverage-4.05-4.05-12.78-15.33-46.28—————

ADPT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio3.343.342.894.665.123.546.917.827.939.77
Quick Ratio3.233.232.814.504.993.376.787.717.589.54
Cash Ratio2.522.522.273.944.543.106.547.377.249.15
Asset Turnover—0.540.330.260.220.170.090.090.170.11
Inventory Turnover7.277.278.545.234.012.561.602.462.513.27
Days Sales Outstanding—66.3785.1181.3978.9041.1737.2754.3931.5252.99

ADPT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield——————————
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield——————————
FCF Yield———————1.3%——
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$152M$147M$144M$143M$140M$131M$124M$105M$105M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Thin liquidity against rising debt

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Against Negative Earnings

Based on reported figures, ADPT trades at a trailing P/S of 14.97 and P/B of 18.79 while TTM P/E is negative at -73.85, a combination that prices in revenue durability and a future margin inflection rather than current earnings.

Because the P/E is meaningless with losses, the price-to-sales multiple becomes the operative anchor, and at roughly 15 times trailing sales the market appears to be assigning substantial value to the immune medicine platform and clonoSEQ growth. The P/B of 18.79 against equity of only about $176M suggests the stock is valued far above book, which investors should interpret as a bet on future cash generation rather than asset backing. Multiples of this magnitude warrant further investigation into whether forward revenue assumptions are realistic given the unreconciled profitability claims.

Gross Margin Strength Versus Operating Drag

As reported in quarterly statements, gross margin expanded from 55.3% in 2024Q2 to 76.2% in 2026Q3, yet operating margin of -0.5% in the latest quarter still signals that overhead has only recently approached revenue levels.

The gross margin trajectory is structurally encouraging and consistent with a high-value diagnostic service carrying low variable sequencing cost. However, the operating margin remained deeply negative at -22.0% in 2026Q2 and -20.6% on a trailing basis, which indicates R&D and SG&A still absorb most of the gross profit. The apparent breakeven quarter should be treated cautiously, since the net margin of 3.4% sits well above operating margin, suggesting non-operating items drove the result.

Debt Scaling Faster Than Earnings Capacity

According to recent SEC filings, ADPT's total debt rose from $84.4M in 2025Q2 to roughly $409M in 2026Q3, while interest coverage remains negative at -0.91, indicating operating earnings do not currently cover interest obligations.

Debt/equity of 2.22 in the latest quarter, versus 0.40 to 0.47 through 2025, reflects a sharp shift in capital structure that the income statement has not yet offset. Negative interest coverage means debt service depends on cash reserves or new financing rather than operating earnings. This pattern suggests refinancing and covenant risk should be monitored closely, though the exact terms are not disclosed in the provided data.

Comfortable Current Ratio, Thin Cash Cushion

As reported in financial statements, the current ratio of 3.97 and quick ratio of 3.87 in 2026Q3 look strong, yet cash of about $75.6M is modest relative to recurring operating losses and a rapidly expanded debt load.

The high current ratio is largely supported by receivables and other current assets rather than a deep cash reserve, so headline liquidity may overstate true stress resilience. Under a severe downturn, the cash balance would likely cover only a limited period of burn, suggesting the company could face pressure to raise capital or reduce spending. Investors should weigh the current ratio against the cash runway rather than treat it as evidence of durable solvency.

Misapplied Current Ratio Masks Cash Risk

The current ratio is most commonly misapplied to ADPT because it counts receivables and inventory-like assets as liquidity, which may flatter a company whose ability to meet obligations depends on converting sales into cash.

For a diagnostic business with a DSO of 64 days and a cash conversion cycle of 84 days, receivables are not immediately available to fund operating losses or debt service. A cash ratio or months-of-runway measure, computed against trailing operating cash burn, would better reveal whether the 3.97 current ratio reflects durable liquidity. Using such an adjusted metric would likely show a tighter position than the headline ratio implies.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open ADPT Terminal

ADPT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ADPT — Frequently Asked Questions

Quick answers to the most common questions about buying ADPT stock.

What is Adaptive Biotechnologies Corporation's P/E ratio?

Adaptive Biotechnologies Corporation's current P/E ratio is -75.4x. This places it at the 50th percentile of its historical range.

What is Adaptive Biotechnologies Corporation's ROE?

Adaptive Biotechnologies Corporation's return on equity (ROE) is -27.8%. The historical average is -40.4%.

Is ADPT stock overvalued?

Based on historical data, Adaptive Biotechnologies Corporation is trading at a P/E of -75.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Adaptive Biotechnologies Corporation's profit margins?

Adaptive Biotechnologies Corporation has 74.2% gross margin and -20.6% operating margin.